2025 Program

At BIO 2026, where science meets real-world impact, you can access more than 135 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators and patient advocates.

The 2026 Program will be announced in mid-March. Explore our sessions and speakers from 2025 in the agenda below to see the caliber of programming you can expect at BIO 2026.

Loading
9:00 AM (ET)
  1. Biotech startups emerging from universities are at the forefront of innovation, pushing the boundaries of science and medicine. However, translating groundbreaking research into viable commercial prod ...
    Breakout Session
    • Translational Research
  2. As AI becomes integral to healthcare, ensuring transparency and trust through regulatory compliance is critical. Multi-agent systems, where different AI agents specialize in distinct tasks, are gainin ...
    Breakout Session
    • AI and Digital Health
  3. Currently, the biotech M&A market is subject to a confluence of unique historic forces, both promoting and opposing M&A. Some of these forces include unprecedent M&A demand from big pharma due to the ...
    Breakout Session
    • Business Development and Investment
  4. Back by popular demand, this high-impact session returns to BIO and will guide health and science executives through a proprietary framework developed by LaVoieHealthScience: The LHS Fifteen-Slide Pre ...
    Breakout Session
    • Business Development and Investment
  5. The Human Genome Project led to an explosion of knowledge about the genetic roots of disease. Now leaders in genetic medicine technologies, including RNAi therapeutics and CRISPR gene editing, are har ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  6. Biotech is entering a new era of mega blockbusters - drugs with peak sales potential exceeding $10 billion. Drug developers are increasingly focusing on novel therapies that can reach the largest poss ...
    Breakout Session
    • Business Development and Investment
  7. The Accelerated Approval Program has been the focus of many recent conversations questioning the impact and value of the pathway for patients. Drugs approved via this pathway have become the latest vi ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
  8. The tremendous success of GLP-1/GIP receptor agonists has ushered in a rapid paradigm shift in how we consider and treat chronic metabolic diseases, like obesity and associated comorbidities. These th ...
    Breakout Session
    • Next Generation Biotherapeutics
  9. Join us for a dynamic panel discussion exploring the evolution of investment in medical and healthcare interventions designed to advance health equity. In a competitive market, focus on equity during ...
    Breakout Session
    • Diversity and Opportunity
  10. The global immunology market is projected to nearly double by 2032, expanding from $250 billion in 2023. Immunology and Inflammation (I&I) has now emerged as a top investment priority in biopharma, su ...
    Breakout Session
    • Next Generation Biotherapeutics
  11. In recent years, "patient-centric" has emerged as a buzzword in the healthcare world. However, the reality is that our industry has often overlooked the patient voice, which has, at times, impeded the ...
    Breakout Session
    • Regulatory Innovation
  12. This session will delve into how preclinical human data, derived from innovative methodologies such as organ-on-a-chip technology, lab-grown tissues, and advanced imaging techniques, can provide inval ...
    Breakout Session
    • AI and Digital Health
  13. While CAR-T therapies have revolutionized cancer treatment, access remains largely confined to major academic medical centers, limiting treatment availability for most eligible patients. Expanding del ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
  14. An increasing number of cell and gene therapies hold significant promise, but challenges remain in bringing these therapies to patients. These include regulatory, manufacturing and clinical trial chal ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  15. Where there is unmet clinical need, opportunities to develop therapeutics to help the greatest number of patients follow. It is important that the surrounding ecosystem directs biopharmaceutical compa ...
    Breakout Session
    • Patient Advocacy

    Sponsored by:

    astrazeneca

  16. In today’s world, successful therapeutic developers must not only generate clinical data to meet regulatory requirements for approval, they must also demonstrate the value of therapeutic candidates to ...
    Breakout Session
    • Business Development and Investment

    Sponsored by:

    fortrea

  17. Fireside Chat
    Join BIO's Chief Patient Advocate and Head of the Patient Advocacy Center of Excellence, Michele Oshman, for a fireside chat with author of "More Than We Expected: Five Years With a Remarkable Child", ...
    Fireside Chat
    • Patient Advocacy
  18. Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  19. Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  20. BioProcess International Theater
    • Biomanufacturing
    BioProcess Theater
  21. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  22. Spilled Milk - Two lifelong friends. Omar is living with Sickle Cell Disease; Jaqai has uprooted his life to make a documentary about him. Spilled Milk explores the harsh realities of Sickle Cell, bey ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  23. The EU is reshaping its biotechnology landscape, with the focus on competitiveness, supply and capacity resilience and societal benefit. A European Commission 5 year mandate has over 20 legislations a ...
    Breakout Session
    • Emerging Opportunities in Global Markets
  24. Fireside Chat
    In 2022, Congress tasked the National Security Commission on Emerging Biotechnology with assessing how the United States can maintain its global lead in biotech and safeguard our collective security. ...
    Fireside Chat
    • Business Development and Investment
  25. The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  26. The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #3035)
10:00 AM (ET)
  1. After many years of research, AI-supported molecules have started entering clinical trials and the 2024 Nobel Prize in Chemistry recognized the impact of computational biology on reenvisioning the dru ...
    Breakout Session
    • AI and Digital Health
  2. Start-Up Stadium Session
    • Business Development and Investment
  3. Start-Up Stadium Session
    • Business Development and Investment
10:15 AM (ET)
  1. This session will discuss why, contrary to conventional wisdom, the need for co-pay and premium assistance, in this complicated environment, is likely to increase, not decrease, under the IRA. Panelis ...
    Breakout Session
    • Patient Advocacy
  2. Countless preclinical- and clinical-stage drugs remain shelved, not for scientific reasons or because they lack demonstrated potential to help patients, but rather because of strategic, organizational ...
    Breakout Session
    • Business Development and Investment
  3. When innovating toward solutions for the world's greatest health challenges, such as matters of health security, global preparedness, and life-saving health solutions more broadly, time is of the esse ...
    Breakout Session
    • Regulatory Innovation
  4. A new class of conditionally active biologics that is safer and less toxic than existing therapies is emerging. These drugs have the potential to overcome shortcomings of current state-of-the-art ther ...
    Breakout Session
    • Next Generation Biotherapeutics
  5. Emerging modalities are driving the future of the biopharma industry, and pharmaceutical companies are increasingly turning to external sources for these innovations. This panel brings together speake ...
    Breakout Session
    • Business Development and Investment
  6. The industry is still grappling with GenAI while quantum is lurking around the corner. There are already companies and countries experimenting with quantum. From a business perspective, the ways that ...
    Breakout Session
    • AI and Digital Health
  7. New Approach Methodologies (NAMs) are at the forefront of transforming how biomedical research translates into real-world treatments, enabling faster and more precise drug development by, in some case ...
    Breakout Session
    • Translational Research
  8. How can obesity treatments move beyond GLP-1 drugs to offer long-term, patient-friendly solutions? Obesity management is at a pivotal phase, with new opportunities emerging to deliver sustainable weig ...
    Breakout Session
    • Next Generation Biotherapeutics
  9. Immunology is entering a new era, presenting unique investment prospects as therapeutic innovations emerge and investors are eager to participate in this attractive field. Next generation I&I therapie ...
    Breakout Session
    • Business Development and Investment
  10. As the pharmaceutical industry increasingly embraces AI in drug discovery, a pressing question emerges: can AI go beyond merely delivering faster and cheaper drugs? Join our expert panel of C-level ex ...
    Breakout Session
    • AI and Digital Health
  11. The Inflation Reduction Act (IRA) has caused strong disruption to innovation in drug development, and this impact is falling heaviest on oncology and neuroscience. Cancer drug development has been rem ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
  12. The recent landmark success of gene-edited porcine kidney transplants into human recipients marks a turning point in the future of organ transplantation. With genetic engineering enabling immune-compa ...
    Breakout Session
    • Business Development and Investment
  13. CAR-T and other advanced therapies hold transformative, and even curative potential, however reimbursement bottlenecks are preventing widespread access. Payer hesitation, regulatory complexity, and ot ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
  14. The Rare Disease Innovation Hub, established by the FDA in 2024, serves as a pivotal point of collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Eval ...
    Breakout Session
    • Orphan and Rare Disease
  15. In the rapidly evolving landscape of cell and gene therapy, the journey from clinical development to commercial launch presents unique challenges and opportunities. This session will provide attendees ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing

    Sponsored by:

    cencora

  16. With more than 30 approved gene and cell therapy (GCT) products and the rapid emergence of new GCT technologies, academic medical centers (AMCs) play a crucial role in advancing genetic medicines. How ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  17. Food is medicine—and yet, for millions, it’s out of reach. Since 2021, the Greater Boston Food Bank has led the way and conducted an annual survey of Massachusetts households to determine the rates an ...
    Special Program
    • Patient Advocacy
  18. “The Next Frontier,” a new branded film series produced by BBC StoryWorks and presented by BIO, explores how biotechnology is shaping the future of health, climate, and food, but if public understandi ...
    Special Program
    • Next Generation Biotherapeutics
  19. What makes a partnership work in vaccine development? When is it the right stage to partner programs? How do you identify strategic partner fits? With its own unique ecosystem, vaccine development and ...
    Breakout Session
    • Infectious Disease and Vaccines

    Sponsored by:

    novavax

  20. Super Session
    Whether it is FDA, tariffs, interest rates or geopolitical uncertainty, the macro has been exerting significant pressure on the biotech industry. Will there be widespread consolidation in the number o ...
    Super Session
    • Special Program
  21. Following his fireside chat, join James Robinson for a book signing and meet and greet. Complimentary copies of the books will be available at the signing on a first come, first served basis. Book sig ...
    Special Program
    • Patient Advocacy
  22. This interactive session is designed to provide students with the guidance and connections needed to navigate entry into the biotech industry. Panelists will share their personal career journeys and i ...
    Special Program
    • Business Development and Investment
  23. Legal challenges, directives from elected and appointed leaders, and public funding reductions have intensified in recent months. How do companies remain compliant and committed to their missions? Wha ...
    Breakout Session
    • Diversity and Opportunity
  24. Successful collaborations among biopharmaceutical companies, patient advocacy organizations, and other key stakeholders help to de-risk drug development and can avoid potentially perilous roadblocks l ...
    Breakout Session
    • Patient Advocacy
  25. AI holds immense promise for helping us bring medicines to patients faster, but only if we confront the growing data dilemma. Specifically, as we aim for AI to impact each step of the drug discovery a ...
    Breakout Session
    • AI and Digital Health

    Sponsored by:
    millipore sigma

10:30 AM (ET)
  1. Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  2. BioProcess International Theater
    • Biomanufacturing
    BioProcess Theater
  3. Global Innovation Hub Session
11:00 AM (ET)
  1. The US life science industry and ecosystem have been an unparalleled engine for transformative medical innovation since the passage of the Bayh-Dole Act in 1980. Since then and through 2022, fueled by ...
    Breakout Session
    • AI and Digital Health
  2. “Insanity is doing the same things over and over but expecting different results,” Rita Mae Brown. Most of us would agree. And yet, year after year, we invest over $90 billion in R&D, only to face a s ...
    Breakout Session
    • Oncology
  3. In recent years, public health advocacy has played an increasingly critical role in shaping legislation and policy decisions regarding vaccines. Shifting political landscapes, public opinion, and misi ...
    Breakout Session
    • Infectious Disease and Vaccines
  4. From R&D, regulatory approval pathways to considerations for launching cell and gene therapies, this session is intended to shed a light on European and Middle Eastern (focus on Saudi Arabia and UAE) ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  5. As the demand for personalized therapies increases, the ability to efficiently produce living medicines at scale is more critical than ever. This session will explore cutting-edge advancements in biom ...
    Breakout Session
    • Biomanufacturing
  6. Developing innovative diagnostic tests that address unmet clinical needs and improve upon standards of care requires a significant investment of time and resources. Precision medicine companies willin ...
    Breakout Session
    • Diagnostics and Personalized Medicine
  7. How do venture capitalists evaluate early stage life science companies to decide where to place their bets? Learn how high-profile VCs evaluate startups, and what data sets are most important for earl ...
    Breakout Session
    • Business Development and Investment
  8. This panel of iconic healthcare and life sciences investors will share their perspectives on top areas for AI and digital health investment. Recent reports show that the number of AI deals in healthca ...
    Breakout Session
    • AI and Digital Health
  9. Women on social media sites (TikTok) have been speaking out about IUD pain, with some describing the procedure as “the worst pain imaginable” or saying they “almost passed out.” Duke University resear ...
    Breakout Session
    • Regulatory Innovation
  10. Fireside Chat
    What does it take to create a new medicine? The trajectory from laboratory to your neighborhood chemist rarely runs in a straight line. Eureka moments come few and far between. Drug discoveries demand ...
    Fireside Chat
    • Business Development and Investment
  11. Public-private partnerships and supportive state legislative measures aimed at growing biomanufacturing capacity in the United States are providing significant economic on-shoring value, and are essen ...
    Special Program
    • Biomanufacturing
  12. The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  13. Since the passage of 21st Century Cures, FDA collaboration with the rare disease patient and scientific community has never been greater. The creation of a Rare Disease Innovation Hub also holds promi ...
    Breakout Session
    • Orphan and Rare Disease

    Sponsored by:

    travere

  14. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  15. Start-Up Stadium Session
    • Business Development and Investment
  16. As the biotech industry faces growing complexity in regulatory expectations and clinical trial innovation, oncology developers must adopt smarter, more agile strategies to advance their pipelines. Pan ...
    Breakout Session
    • Oncology

    Sponsored by:

    parexel biotech

11:30 AM (ET)
  1. Super Session
    Join Anjalee Khemlani (Yahoo Finance) in conversation with Mina Makar, RpH (SVP, Global Cardiovascular, Renal and Metabolism, BioPharmaceuticals Business Unit, AstraZeneca) as they explore the transfo ...
    Super Session
    • Special Program

    Sponsored by:

    astrazeneca

  2. The Next Frontier Films: From pandemic preparedness to food security, climate change to resource scarcity, the world requires innovative solutions to the challenges facing society. With its potential ...
    Storytelling Stage Storytelling Stage (Booth #3035)
12:00 PM (ET)
  1. This session aims to illuminate the cutting-edge technical approaches of AI-driven biologics drug discovery companies. Speakers will explore the ongoing R&D efforts in developing platforms and pipelin ...
    Breakout Session
    • AI and Digital Health
12:15 PM (ET)
  1. Following his fireside chat, join Dr. William Pao for a book signing and meet and greet. Complimentary copies of the books will be available at the signing on a first come, first served basis. Book si ...
    Special Program
    • Business Development and Investment
  2. Super Session
    Biopharma companies encounter crucial commercial barriers as they navigate their assets from molecule to marketplace. In a contemporary landscape where product types and therapies are diversifying, bi ...
    Super Session
    • Business Development and Investment

    Sponsored by:

    cencora

  3. Super Session
    Join as Johnson & Johnson’s Penny Heaton, MD, Global Head of the Johnson & Johnson Office of the Chief Medical Officer, and Nauman Shah, Global Head of Innovative Medicine Business Development, discus ...
    Super Session

    Sponsored by:

    johnson&johnson

12:30 PM (ET)
  1. Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  2. Are the nationalist trends toward investment, trade and national security policies going to divide the world into different spheres of R&D and access to health care products? What impact will they hav ...
    Special Program
    • Special Program
    Main Stage
  3. Biomanufacturing innovations have the potential for high impact, delivering benefits that span financial gains and societal advancements. These breakthroughs can drive increased efficiencies, reduce c ...
    Breakout Session
    • Business Development and Investment
  4. BioProcess International Theater
    • Biomanufacturing
    BioProcess Theater
1:00 PM (ET)
  1. The most powerful health stories don’t just inform—they connect, inspire, and move audiences. By centering the real-life journeys of patients and practitioners, we create narratives that spark emotion ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  2. Eight rare disease families are changing the future of medicine as they pursue their missions to cure the incurable. These inspiring stories of love, loss and determination prove that every one of us ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  3. Start-Up Stadium Session
    • Business Development and Investment
  4. The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #3035)
1:15 PM (ET)
  1. The 35th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotechnology industry’s standing within a quickly evolving transaction and financing envi ...
    Breakout Session
    • Business Development and Investment
  2. Establishing university-industry partnerships enables the realization of ideas and discoveries to become actual products and services that benefit the public. These partnerships present a variety of o ...
    Breakout Session
    • Translational Research
  3. Hear a diverse panel of small investors (angels and small VCs) from around the world discuss the role of smaller investors in the lifecycle of biotechnology startup companies – both in the US and over ...
    Breakout Session
    • Business Development and Investment
  4. Recent data reveals that less than 10% of CEOs in the biopharma industry are women, while female representation in leadership teams stands at 25%. However, the momentum for change is undeniable. A gro ...
    Breakout Session
    • Diversity and Opportunity
  5. Conducting multi-national clinical trials for rare diseases poses ethical and logistical challenges, particularly in ensuring equitable patient access and sustainable commercialization plans. This pan ...
    Breakout Session
    • Orphan and Rare Disease
  6. Integrating real-world evidence (RWE) strategies during drug development and commercialization is critical to maximizing shareholder and stakeholder value. Biopharma executives need to know how to lev ...
    Breakout Session
    • AI and Digital Health
  7. In vivo CAR (Chimeric Antigen Receptor) therapies are poised to revolutionize immunotherapy by moving beyond the limitations of traditional ex vivo approaches. These therapies involve programming immu ...
    Breakout Session
    • Next Generation Biotherapeutics
  8. Biotech goes beyond science - although the building blocks of our industry are made up of groundbreaking approaches that start in the lab, the goal is that they end in one place - impacting patients. ...
    Breakout Session
    • Patient Advocacy
  9. This interactive session is designed to provide students with the guidance and connections needed to navigate entry into the biotech industry. Panelists will share their personal career journeys and i ...
    Student Program
  10. Super Session
    CDMOs play a pivotal role in the rapidly evolving landscape of the pharmaceutical and biotechnology industries, helping them bring innovative therapies and life-saving products to market. Over the nex ...
    Super Session
    • Special Program

    Sponsored by:

    alixpartners

  11. Breakthroughs in biomanufacturing, biochemical modeling, and AI-enabled drug discovery and development could dramatically boost industry-wide productivity—but they require massive early-stage investme ...
    Special Program
    • Biomanufacturing
  12. Biotechnology supply chains are inherently global, spanning research, development, manufacturing, distribution, and skilled workforce networks across multiple countries. This interdependence has drive ...
    Breakout Session
    • Emerging Opportunities in Global Markets
1:30 PM (ET)
  1. This film follows two families as they begin a clinical drug trial that seems to offer the best hope for their children. Both families connect with the STXBP1 community for guidance and support on the ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  2. Join us to hear from our finalists and discover who will receive over $250,000 in bioprocessing technologies, bioprocessing consulting services, contract testing services. The next round of applicatio ...
    Start-Up Stadium Session
1:45 PM (ET)
  1. This panel will explore the vital role of patients and their families in driving innovation in rare disease therapies. By sharing personal experiences and expert insights, panelists will highlight how ...
    Breakout Session
    • Orphan and Rare Disease
  2. Across therapeutic areas, oncology is richest in depth of pipeline and variety of potential modalities/mechanisms of action. Of nearly 200 different products in Phase 3 alone, small molecules are now ...
    Breakout Session
    • Oncology
  3. Biotechnology companies are producing remarkable therapies at an unprecedented pace. In the past year, two new gene therapies have come to market for patients suffering from sickle cell disease. Rapid ...
    Breakout Session
    • Infectious Disease and Vaccines
  4. Since its inception in 1992, the FDA has greenlit nearly 300 new drugs under its accelerated approval pathway, with notable nods in oncology, Alzheimer’s disease, and amyotrophic lateral sclerosis. It ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  5. Artificial intelligence (AI) is already revolutionizing drug discovery and development by accelerating the identification of novel targets, optimizing molecules, and improving the efficiency of clinic ...
    Breakout Session
    • AI and Digital Health
  6. This session will explore how investments and bold bets in accelerated computing, data generation at scale, and model-first strategies are revolutionizing the industry, without ignoring the initial ch ...
    Breakout Session
    • AI and Digital Health
  7. The threat of antimicrobial resistance is growing globally as the use of higher doses and repeated courses of antibiotics drives more resistant bacteria. Yet innovation in infectious disease has been ...
    Breakout Session
    • Infectious Disease and Vaccines
  8. The bioeconomy—encompassing industries that leverage biological resources, processes, and principles—spans sectors such as biotechnology, agriculture, pharmaceuticals, bioenergy, and synthetic biology ...
    Breakout Session
    • Biomanufacturing
  9. The rapid advancement of cell therapies has opened new frontiers in regenerative medicine, but it has also highlighted significant regulatory hurdles across global jurisdictions. One of the most press ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  10. R&D is often the most cost-intensive and risky step in a new drug's life cycle yet often dictates the speed and adaptability of the innovation ecosystem. The time and capital required for biotech to t ...
    Breakout Session
    • Business Development and Investment
  11. The new Unified Patent Court (UPC) system in Europe has been described as a game-changer with respect to patent litigation, particularly when there are infringing activities in both Europe and the Uni ...
    Breakout Session
    • Intellectual Property and Legal Landscape
  12. In a complex and ever-evolving landscape—with shifting regulatory pressures and stakeholder expectations—biotech and pharma companies must continue prioritizing transparency to build trust, maintain a ...
    Breakout Session
    • Environmental Sustainability
  13. The therapeutic use of psychedelics is no longer a pipe dream – they are on the verge of potentially transforming the way we treat brain health disorders. As companies progress psychedelic therapies i ...
    Breakout Session
    • Brain Health
  14. The cancer therapeutics landscape is constantly evolving as breakthroughs across modalities drive toward the shared goal of providing accessible and life-saving treatments to patients. Companies are a ...
    Breakout Session
    • Oncology
  15. In recent years, investors have leaned toward being “risk off” for truly innovative therapies, such as first-in-class or first-in-disease drugs, with a preference for lower-risk drug discovery opportu ...
    Breakout Session
    • Business Development and Investment
  16. Today's undervalued category is tomorrow's over-crowded sector, yet newcomers are emerging. This panel will examine issues, opportunities, and approaches to dealmaking among an emerging generation of ...
    Breakout Session
    • Business Development and Investment
  17. The economics of rare-disease research is a consistent obstacle to progress. Although there are more than 10,000 rare diseases that collectively affect over 30 million people in the United States, eac ...
    Breakout Session
    • Orphan and Rare Disease
  18. Representatives from biotech, academia, patient advocacy, and the investor community will have a robust and interactive discussion about next generation therapies to treat blinding eye diseases that a ...
    Breakout Session
    • Next Generation Biotherapeutics
  19. This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...
    Breakout Session
    • Business Development and Investment
  20. Fireside Chat
    Join us for an exclusive fireside chat with Feng Zhang, PhD, renowned scientist and core member of the Broad Institute, an Investigator at the McGovern Institute for Brain Research, the James and Patr ...
    Fireside Chat
    • Next Generation Biotherapeutics
  21. Extended reality (XR) sensory technologies enhance patient agency. This multi-purpose tool elevates patient education, provider communication, multi-dimensional therapy, and comprehensive assessments. ...
    Special Program
    • AI and Digital Health
  22. Whether you're just starting your career or looking to take the next big step, this session will help you navigate the biotech industry. We will begin with an overview of what biotechnology is and its ...
    Student Program
  23. Super Session
    Strategic partnerships between biotech innovators, VCs and pharmaceutical companies have become the cornerstone of drug development, illustrating a beneficial exchange where cutting-edge research meet ...
    Super Session
    • Business Development and Investment

    Sponsored by:

    novartis

  24. Early drug development presents unique challenges for companies navigating the complexities of clinical programs, regulatory landscapes, and market access. This session will explore key trends impacti ...
    Breakout Session
    • Business Development and Investment

    Sponsored by:

    cencora

  25. Fireside Chat
    Since its founding, Pennsylvania has been a leader in medicine and the life sciences. The first hospital in the United States was established in Philadelphia in 1751 followed by the first school of ph ...
    Fireside Chat
    • Value‚ Patient Access and Reimbursement
  26. This panel will focus on the role of state governments in supporting life sciences innovation in the United States, including programs that are offered at the state level to support international comp ...
    Breakout Session
    • Business Development and Investment
  27. Global Innovation Hub Session
  28. Innovative approaches to medicine require us to reimagine how we bring medicines to patients. This panel will explore the intersection of industry, policy, and the patient community and how collaborat ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement

    alnylam

     

  29. Real-world data (RWD) has long informed clinical research, but traditional sources - electronic health records, claims data, registries - often provide only a partial view of patient health. This can ...
    Breakout Session
    • Diagnostics and Personalized Medicine

    Sponsored by:

    evidation

2:00 PM (ET)
  1. Unconditional: Raising a Glass Child with a PACS1 Sibling - This film introduces the Poague Zellinger family who are facing PACS1 syndrome which affects their five year old son Finn. The phrase glass ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  2. Start-Up Stadium Session
    • Business Development and Investment
  3. Start-Up Stadium Session
    • Business Development and Investment
  4. BioProcess International Theater
    • Biomanufacturing
    BioProcess Theater
2:30 PM (ET)
  1. Won an SBIR/STTR grant from the NIH for your biomedical innovation? A new paradigm for inter-agency, industry, and venture capital collaboration is here to help commercialize it! Startups are 50% more ...
    Breakout Session
    • Business Development and Investment
  2. This session will delve into the intricate landscape of the US legal and regulatory framework governing the use of artificial intelligence (AI) in pharmaceutical product development. As AI continues t ...
    Breakout Session
    • Regulatory Innovation
  3. Rare disease clinical trials face unique challenges, including small patient populations, high variability in disease presentation, and logistical complexities. This panel will explore innovative stra ...
    Breakout Session
    • Orphan and Rare Disease
  4. With the development of RNA therapeutics advancing at an unprecedented pace, the healthcare and pharmaceutical industry is entering an “RNAissance” era. RNA, a molecule that was viewed as a transient ...
    Breakout Session
    • Next Generation Biotherapeutics
  5. Computational methods including AI/machine learning have the potential to be transformational in biopharma by accelerating and enhancing many aspects of drug discovery to bring better drug candidates ...
    Breakout Session
    • AI and Digital Health
  6. Whether setting a course or changing strategies in today's biopharma landscape, information overload, quickly obsolete insight, and stakeholder misalignment are industry-wide challenges. As an emergin ...
    Breakout Session
    • Business Development and Investment
  7. Since 2008, Massachusetts has made significant financial, policy, and people investments in the life sciences, including building a broad-based effort to expand pathways to produce diverse talent to d ...
    Breakout Session
    • Diversity and Opportunity
  8. While huge advances have been made in ensuring optimal patient care in oncology where diagnostic testing is required prior to initiation of therapy (i.e. precision medicine), we continue to see practi ...
    Breakout Session
    • Diagnostics and Personalized Medicine
  9. The Foundation for the NIH (FNIH) creates and leads alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people’s lives. Building on a ...
    Breakout Session
    • Business Development and Investment
  10. America risks falling behind in biotechnology because it hasn't treated the sector as a strategic priority—unlike semiconductors or AI. For example, the currently fragmented and opaque regulatory syst ...
    Special Program
    • Regulatory Innovation
  11. The Asia Pacific region is rapidly becoming a global force in healthcare and biotech innovation—fueled by resilient capital flows and propelled by its rising scientific capabilities, diverse patient p ...
    Breakout Session
    • Emerging Opportunities in Global Markets

    Sponsored by:

    johnson&johnson

  12. Super Session
    On May 12, 2025, the Trump Administration announced a new Executive Order, “Delivering Most Favored Nation Prescription Drug Pricing to American Patients.” This was followed by an announcement on May ...
    Super Session
    • Special Program
  13. Emerging companies are the lifeblood of biotech innovation. Over time, the share of FDA-approved therapies originating from small and mid-sized biotech companies has grown steadily, now accounting for ...
    Special Program
    • Special Program
3:00 PM (ET)
  1. Initially drafted in January 2023 and finalized in August 2024, the US Food and Drug Administration (FDA) released guidance tied to Project Optimus, titled “Optimizing the Dosage of Human Prescription ...
    Breakout Session
    • Oncology
  2. For too long, psychiatry has relied solely on clinical observation to prescribe treatments, overlooking the biological differences that impact how patients respond to medication. This trial-and-error ...
    Breakout Session
    • Brain Health
  3. Recent Nobel Prizes in deep learning, structure prediction, microRNA, and mRNA signal that the pharmaceutical industry is entering a new era of innovation, driven by the rapid rise of generative and f ...
    Breakout Session
    • AI and Digital Health
  4. siRNA, mRNA, pick-your-favorite-RNA, CRISPR, ADCs, PROTACs, molecular glues, precision-meds, CAR-T, epigenetic and allosteric modulators, AI/ML-everything, tissue-selective nanoparticles, AAV delivery ...
    Breakout Session
    • Business Development and Investment
  5. Originally pioneered as lifesaving treatments for patients with cancer, cell therapies have burst onto the biotech scene as promising, disease-eliminating treatments for autoimmune disorders – a notor ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  6. Cell and gene therapies (CGT) are proving their worth as life-saving treatments, from cancers to rare diseases, but bringing these innovations to the masses will require substantial advances in manufa ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  7. This session will explore how CEPI (Coalition for Epidemic Preparedness Innovations) and its global partners mobilize during an outbreak, highlighting how strategic partnerships and rapid vaccine deve ...
    Breakout Session
    • Infectious Disease and Vaccines
  8. Over the past decade, European biotech has seen remarkable growth, driven by increasing early-stage investments and the creation of promising start-ups. VIB, a leading life sciences research institute ...
    Breakout Session
    • Business Development and Investment
  9. While the industry is moving forward with the blending of technology and science, the legal landscape is quite different in one of the largest markets: the United States. The Loper Bright ruling this ...
    Breakout Session
    • Intellectual Property and Legal Landscape
  10. Artificial intelligence (AI) and related technologies offer new avenues of drug discovery productivity never before possible. These innovative methods not only provide significant value to the biophar ...
    Breakout Session
    • Biomanufacturing
  11. Healthcare AI as we know it is evolving at a rapid pace, with major tech company initiatives, overheated equity investment and the next generation of innovation fanning the flames. How can NIH and maj ...
    Breakout Session
    • AI and Digital Health
  12. The legal challenges to the Inflation Reduction Act are now mature. It is critical to assess, at this inflection point, what they have and have not accomplished. As cases move from the District Courts ...
    Breakout Session
    • Intellectual Property and Legal Landscape
  13. For biotech companies planning an IPO, navigating market dynamics, investor expectations, and regulatory hurdles is critical to success. This session brings together industry leaders to share insights ...
    Breakout Session
    • Business Development and Investment
  14. Nearly a quarter of adults in the United States report difficulty affording prescription drugs which is often attributed to the drug’s price set by the manufacturer rather than to the patient out-of-p ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
  15. This panel will explore the opportunities and hurdles in the dynamic field of advanced biologics manufacturing, where innovative technologies intersect with medical advancements. This domain offers si ...
    Breakout Session
    • Biomanufacturing
  16. Fireside Chat
    Even now, nearly a century after her death, Marie Curie remains the only female scientist most people can name. She gained world renown at age thirty-six, when she received the first of her two Nobel ...
    Fireside Chat
    • Oncology
  17. Partnering with innovative companies at all stages of development is core to how we discover and develop new groundbreaking medicines. Establishing those deep and successful partnerships presents nume ...
    Breakout Session
    • Business Development and Investment

    Sponsored by:

    genentech

  18. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  19. In today’s global economy it is imperative U.S. companies maintain a competitive advantage by understanding industry developments across global markets. The most successful companies embrace internati ...
    Breakout Session
    • Business Development and Investment
  20. The completion of two seasons of RSV immunization for infants provides us with an opportunity to reflect on ways to enhance policies, programs, and systems to maximize protection for infants. Successf ...
    Breakout Session
    • Infectious Disease and Vaccines

    Sponsored by:

    merck

  21. Extended reality (XR) sensory technologies enhance patient agency. This multi-purpose tool elevates patient education, provider communication, multi-dimensional therapy, and comprehensive assessments. ...
    Special Program
    • AI and Digital Health
  22. One Shot to Live - Single-gene therapy may be the greatest hope for thousands of children with rare diseases. But the greatest challenge is time, or the lack of it. The parents of these children fight ...
    Storytelling Stage Storytelling Stage (Booth #3035)
  23. The evolving regulatory landscape is opening new doors for biopharma companies to bring therapies to market faster and more efficiently. Programs like the FDA’s Advanced Manufacturing Platform (AMT), ...
    Breakout Session
    • Emerging Opportunities in Global Markets

    Sponsored by:

    cytiva

  24. Revolutionary breakthroughs in genetic science have transformed what was once a futuristic approach into an attainable shift in the medical paradigm. Today’s tools enable diagnosis and individualized ...
    Breakout Session
    • Next Generation Biotherapeutics
  25. Biotechnology is reshaping economies and healthcare systems across the globe, and governments are investing heavily to build national capabilities. Yet at the same time, shifting trade dynamics and ev ...
    Breakout Session
    • Emerging Opportunities in Global Markets
  26. Cancer care is at a pivotal moment. Breakthroughs in precision medicine, immunotherapy, artificial intelligence and data-driven diagnostics are transforming how we detect, treat and manage cancer. Yet ...
    Breakout Session
    • Oncology

    Sponsored by:

    merck

3:30 PM (ET)
4:15 PM (ET)
  1. In 1901, the first Nobel Prize was awarded to recognize those who “have conferred the greatest benefit to humankind.” Often the work that goes into winning this prestigious award occurs over decades a ...
    Breakout Session
    • Translational Research
  2. The rapid advancement of DNA foundation models is transforming our ability to decode complex genomic patterns and regulatory mechanisms. This session will explore the current state of these models, th ...
    Breakout Session
    • AI and Digital Health
  3. According to the most recently available figures, more than 2,000 new oncology clinical trials have begun since 2023, demonstrating the continued need for innovative and effective cancer therapies. Wh ...
    Breakout Session
    • Oncology
  4. This session will explore the priority review voucher (PRV) program as proposed in a 2006 paper by Ridley, Grabowski, and Moe and became law in 2007. The PRV allowed the FDA to encourage R&D in neglec ...
    Breakout Session
    • Business Development and Investment
  5. The commitment to women’s health has been increasing over the past year from the US government and dedicated early-stage seed funds. As this funding is deployed to promote innovation and provide solut ...
    Breakout Session
    • Business Development and Investment
  6. Intellectual property rights are the bedrock of life-science innovation. But attacks on numerous fronts, from pervasive anti-patent myths to attempts to misuse march-in rights, now threaten to erode t ...
    Breakout Session
    • Intellectual Property and Legal Landscape
  7. This past year has seen many early-stage deals involving platform technologies ranging from AI drug discovery to building blocks for gene therapy products. In this panel, speakers will explore platfor ...
    Breakout Session
    • Business Development and Investment
  8. There is much to be said for the humanitarian impulse to expand access to life-saving medicines in resource challenged geographies, but the realities on the ground tell us that the humanitarian impuls ...
    Breakout Session
    • Emerging Opportunities in Global Markets
  9. The session explores novel technologies and public-private partnerships that can end deaths from influenza in our lifetime. Last flu season saw illnesses, medical visits, hospitalizations, and deaths ...
    Breakout Session
    • Infectious Disease and Vaccines
  10. Co-discovery and co-development partnerships have become a cornerstone of the biopharma industry. These partnerships can unlock the potential for groundbreaking medicines, yet their scientific complex ...
    Breakout Session
    • Business Development and Investment
  11. As biological threats evolve, traditional stockpiling strategies need to adapt to ensure both readiness and flexibility. This session will delve into dual-use models that serve commercial and public h ...
    Breakout Session
    • Business Development and Investment
  12. Getting a foothold in the biotech industry isn’t easy. If you have a game-changing biotech idea that will make a difference for cancer patients, you’ll need funding and entrepreneurship expertise to t ...
    Breakout Session
    • Oncology
  13. As it has touched so many different areas of human activity, so has artificial intelligence (AI) touched biotechnology and, by extension, biotechnology intellectual property. Panelists will discuss th ...
    Breakout Session
    • Intellectual Property and Legal Landscape
  14. Why are so many drug discoveries still failing to make it out of the lab when the speed of, and competition for, innovation has never been higher? Could solving this challenge lie in the unique relati ...
    Breakout Session
    • Translational Research
  15. We are witnessing a revolution in rare disease drug development. Traditional models fall short due to small patient populations and limited disease understanding. However, regulatory agencies are now ...
    Breakout Session
    • Orphan and Rare Disease
  16. Biopharma’s ability to create new drugs has depended, from the start, on our collective knowledge of Earth’s genetic biodiversity. While many existing datasets have sought to describe the world, they ...
    Breakout Session
    • AI and Digital Health
  17. In a recent survey, overall partner ratings by large pharma customers were much higher in comparison to ratings given by smaller biotechs, displaying a potential disparity in how partner organizations ...
    Breakout Session
    • Biomanufacturing
  18. A steady and impressive track record of growth in the life sciences industry has kept access to a skilled, diverse workforce at top of mind for life science leaders, even amid occasional retractions. ...
    Breakout Session
    • Diversity and Opportunity
  19. As the search for effective treatments for Alzheimer’s disease intensifies, join us for a compelling panel discussion on the next-generation therapies reshaping the landscape of this devastating condi ...
    Breakout Session
    • Brain Health
  20. As gene editing and epigenetics evolve, they are not only transforming how we approach complex diseases but also unlocking new possibilities for enhancing longevity, healthspan, and even organ transpl ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
  21. Following her fireside chat, join Dava Sobel for a book signing and meet and greet. Complimentary copies of the books will be available at the signing on a first come, first served basis. Book signing ...
    Special Program
    • Special Program
  22. Super Session
    This session will open with an overview of Vision 2030 and explanation of the Kingdom’s commitment to the role of biotech in advancing healthcare. A panel discussion will then explore the key drivers ...
    Super Session

    Sponsored by:

    saudi biotech

     

  23. Extended reality (XR) sensory technologies enhance patient agency. This multi-purpose tool elevates patient education, provider communication, multi-dimensional therapy, and comprehensive assessments. ...
    Special Program
    • AI and Digital Health
  24. For too long, women’s health has been overlooked, in research, in funding, and in the way we understand disease. But the science is clear: understanding sex differences doesn’t just improve health out ...
    Special Program
    • Special Program
  25. Hear from Advanced Research Projects Agency for Health (ARPA-H) leadership and agency program and project performers as they discuss the agency’s efficient and unique model to fund health-related rese ...
    Breakout Session
    • Business Development and Investment
  26. Storytelling is a powerful way to connect, and a critical skill for leaders and advocates today. The Moth is an acclaimed nonprofit organization dedicated to the art and craft of true, personal storyt ...
    Special Program
    • Special Program
  27. Fireside Chat
    The biotechnology sector is evolving rapidly, driven by breakthroughs in science, shifts in policy, and growing demand for resilient healthcare systems. In this fireside chat, EU Health and Animal Wel ...
    Fireside Chat
    • Emerging Opportunities in Global Markets
  28. This panel will provide a multidimensional, internal look at how different groups across Novo Nordisk collaborate to expand the options available for improving treatments of obesity and diabetes to he ...
    Breakout Session
    • Business Development and Investment

    Sponsored by:

    novo nordisk

  29. This session explores the cutting-edge trends and strategic decisions transforming the modern biotech industry. Our expert panelists will dive into the most impactful technological innovations in larg ...
    Breakout Session
    • Biomanufacturing

    Sponsored by:

    thermofisher scientific

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS

Loading